FNCH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FNCH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Finch Therapeutics Group's change in receivables for the quarter that ended in Mar. 2024 was $0.00 Mil. It means Finch Therapeutics Group's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .
Finch Therapeutics Group's change in receivables for the fiscal year that ended in Dec. 2023 was $0.14 Mil. It means Finch Therapeutics Group's Accounts Receivable declined by $0.14 Mil from Dec. 2022 to Dec. 2023 .
Finch Therapeutics Group's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Finch Therapeutics Group's liquidation value for the three months ended in Mar. 2024 was $-10.29 Mil.
The historical data trend for Finch Therapeutics Group's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Finch Therapeutics Group Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Change In Receivables | 0.05 | 3.65 | 0.60 | 0.35 | 0.14 |
Finch Therapeutics Group Quarterly Data | ||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Change In Receivables | Get a 7-Day Free Trial | 0.04 | 0.11 | - | - | - |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.11 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Finch Therapeutics Group (OTCPK:FNCH) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Finch Therapeutics Group's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 0 | / | 0 | * | 91 |
= |
2. In Ben Graham's calculation of liquidation value, Finch Therapeutics Group's accounts receivable are only considered to be worth 75% of book value:
Finch Therapeutics Group's liquidation value for the quarter that ended in Mar. 2024 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 20.762 | - | 31.054 | + | 0.75 * 0 | + | 0.5 * 0 |
= | -10.29 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Finch Therapeutics Group's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeffery A Smisek | director | 1600 SMITH STREET, HQSEO, HOUSTON TX 77002 |
Susan E Graf | director | 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139 |
Lance E Thibault | officer: Chief Financial Officer | |
Matthew P. Blischak | officer: Chief Executive Officer | C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SOMERVILLE MA 02143 |
Joseph Vittiglio | officer: Chief Business & Legal Officer | C/O BLUEBIRD BIO, INC., 455 GRAND UNION BLVD, SOMERVILLE MA 02145 |
Marc Blaustein | officer: Chief Operating Officer | C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SUITE 400, SOMERVILLE MA 02143 |
Domenic J Ferrante | director | BROOKSIDE CAPITAL MANAGEMENT LLC, JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116 |
Samuel A Hamood | director | C/O TRANSUNION, 555 WEST ADAMS STREET, CHICAGO IL 60661 |
Joanne L. Viney | director | C/O HARPOON THERAPEUTICS, INC., 131 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Nicholas Haft | director | C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SUITE 400, SOMERVILLE MA 02143 |
Christian H. Lange | director | 28 HAVEMEYER PLACE, GREENWICH CT 06830 |
Crestovo Investor Llc | director, 10 percent owner | 28 HAVEMEYER PLACE, GREENWICH CT 06830 |
Gregory D Perry | officer: Chief Financial Officer | C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451 |
Chris Shumway | director, 10 percent owner | 28 HAVEMEYER PLACE, GREENWICH CT 06830 |
Zain Kassam | officer: Chief Medical Officer | C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SUITE 400, SOMERVILLE MA 02143 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 07-08-2022
By Stock market mentor Stock market mentor • 01-24-2023
By sperokesalga sperokesalga • 06-09-2023
By GuruFocusNews GuruFocusNews • 07-02-2022
By PRNewswire PRNewswire • 06-13-2023
By GuruFocusNews GuruFocusNews • 06-08-2022
By GuruFocusNews GuruFocusNews • 07-05-2022
By GuruFocusNews GuruFocusNews • 06-12-2022
By sperokesalga sperokesalga • 03-23-2023
By GuruFocusNews GuruFocusNews • 06-18-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.